DiabetOmics opens its first manufacturing facility in Hyderabad
Hyderabad, March 7th, 2018: DiabetOmics, a global medical diagnostics company that is developing the world’s first patented non-invasive, saliva-based diabetes monitoring test has opened its first manufacturing facility in Hyderabad. Hon’ble Minster for IT, Municipal Administration & Urban Development, Industries & Commerce, Public Enterprises, Shri. K.T.Rama Rao inaugurated this facility on Saturday. DiabetOmics will utilize this facility to commercialize their highly accurate, easy-to-use, bluetooth-enabled and non-invasive diabetes point of care (POC) tests and maternal health tests in India and around the world. Ventureast invested about 4 million in DiabetOmics in 2015.
This new facility, which is situated in a three acreplot in Muppireddipally will directly employ about 100-120 people. The overallcapacity of the plant will be to produce 8-10 million test strips a yearand 10,000 to 15,000 assembled readers to begin with. The company hascompleted construction of their world-class manufacturing plant and thetechnology transfer from USA. The commercial production is expected tobegin in the next quarter this year and will target the Indian and Europeanmarkets.
The global burden of diabetics is over 375 million,with India (72 million) and China (109 million) as major epicenters fordiabetes. Dr. Srinivasa Nagalla, CEO of DiabetOmics Inc.,said “We are pleased to bring these innovative diagnostic tests to themarket beginning later part of this year which will be a huge paradigm shiftfor the patients around the world particularly for emerging countries likeIndia where the affordability of quality care is a major burden for many lowincome families”.
In addition to saliva-based diabetes tests, thecompany is currently developing point-of-care tests for rapid screening of TypeI diabetes and early detection of diabetic kidney and eye complications. Acrossthe world, it has been identified that Preeclampsia is the second leading causeof maternal death and gestational diabetes which is a common prenatalcomplication affecting 16 percent pregnancies.
Mr. Venkatadri Bobba, Director- DiabetOmics &General Partner, Ventureast said, “DiabetOmics hascome a long way from the discovery of the Salivary Glycoproteins as the bestbiomarkers for Glycemic Index to product and Bluetooth-enabled readers. The newplant will be in full compliance with global regulatory requirements and willshowcase high quality and low cost manufacturing capabilities of our highlyqualified & well trained staff and the ecosystem enabled by the State ofTelangana. Most importantly, it is gratifying to note that many patients andtheir families could benefit from our innovations beginning later part of thisyear.”
Dr. Varaprasad Reddy, Founder Shantha Biotech andChairman Diabetomics India said, “We are excitedthat our manufacturing facility has been built, technology transferred, withinmonths of getting the CE Mark (European approvals) and start supplying theproducts to the needy patients in just about 2 years from the date of layingfoundation stone in Feb 2016. We are happy to bring this innovativenon-invasive testing which is free of pain and patient friendly to the market.”